Who is sponsoring NCT05064839?

NCT05064839 is sponsored by Poitiers University Hospital.

What drugs are being tested in NCT05064839?

Interventions in NCT05064839: Bony scintigraphy.

What condition does NCT05064839 study?

NCT05064839 studies Transthyretin Cardiac Amyloidosis.

Is NCT05064839 still recruiting?

NCT05064839 is currently completed. Last updated 11 September 2023.

Last reviewed 2023-09-11 · How we verify

NCT05064839: IMPACT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)

Completed Phase 3 Last updated 11 September 2023

What this trial tests

Phase 3 trial testing Bony scintigraphy in Transthyretin Cardiac Amyloidosis in 553 participants. Completed in 18 August 2023.

Timeline

6 October 2021

Primary endpoint
18 August 2023

18 August 2023

Quick facts

Lead sponsor	Poitiers University Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	553
Start date	6 October 2021
Primary completion	18 August 2023
Estimated completion	18 August 2023
Sites	1 location across France

Drugs / interventions tested

Bony scintigraphy

Conditions studied

Transthyretin Cardiac Amyloidosis — all drugs for Transthyretin Cardiac Amyloidosis →

Sponsor

Poitiers University Hospital

Who can join

60 and older, any sex, with Transthyretin Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heart failure with preserved ejection and hypertrophic cardiomyopathy are common diseases and often associated with transthyretin cardiac amyloidosis (TTR-CM), especially in elderly people. Nevertheless, research of TTR-CM is recommended in patients with ventricular hypertrophy without other cause such as valvular disease or hypertension. Therefore, the exact prevalence of TTR-CM remains unknown. We aim to determine the prevalence of TTR-CM in patients with ventricular hypertrophy and aged ≥ 60 years old, hospitalized in our cardiology department (CHU de Poitiers) by performing bone scintigraphy and research of AL amyloidosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Transthyretin Cardiac Amyloidosis

Currently open trials in the same condition.

NCT05797857 — Exercise Training in Transthyretin Cardiac Amyloidosis · NA · recruiting
NCT05489523 — Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic · Phase 4 · recruiting

Other Poitiers University Hospital trials

Trials by the same sponsor.

NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05064839 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
Last refreshed: 11 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05064839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing